Drug Interaction study between AZD3355 and Nexium
Study identifier:D9120C00016
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An open, randomised, three period cross, single centre, phase 1 pharmacokinetic interaction study of the reflux inhibitor AZD3355 150 mg bid and esomeprazole 40 mg od after 7 days of treatment in healthy volunteers
Medical condition
Gastroesophageal Reflux Disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3355, Esomeprazole
Sex
All
Actual Enrollment
30
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Mar 2008
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 AZD3355 150 mg | Drug: AZD3355 150 mg bid, oral, 7 days Other Name: Lesogaberan |
| Experimental: 2 Esomeprazole 40mg | Drug: Esomeprazole 40 mg od, oral, 7 days Other Name: Nexium |
| Experimental: 3 AZD3355 150mg/Esomeprazole 40mg | Drug: AZD3355 150 mg bid, oral, 7 days Other Name: Lesogaberan Drug: Esomeprazole 40 mg od, oral, 7 days Other Name: Nexium |
Contacts
Investigators
Principal Investigator
Eva Ersdal
AstraZeneca R&D, Mölndal, Sweden
